Expression of RUNX3 gene and miR-363 in colorectal cancer and the relationship with clinicopathological features

Li,Guofeng

doi:10.3892/ol.2019.10566

Expression of RUNX3 gene and miR-363 in colorectal cancer and the relationship with clinicopathological features

Authors:
- Guofeng Li
View Affiliations

Affiliations: Department of Anorectal Surgery, The First People's Hospital of Xiaoshan Hangzhou, Hangzhou, Zhejiang 311225, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/ol.2019.10566
Pages: 2278-2285
Copyright: © Li . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of RUNX3 gene and miR-363 in colorectal cancer was studied to explore its relationship with clinicopathological characteristics of colorectal cancer and to analyze the value of RUNX3 combined with miR-363 in the diagnosis of colorectal cancer. In total, 85 patients diagnosed with colorectal cancer in the First people's Hospital of Xiaoshan Hangzhou from March 2014 to July 2016 were the experiment group. Seventy healthy individuals who underwent physical examination were the control group. RT-qPCR was used to detect the expression levels of RUNX3 gene and miR-363 in peripheral blood of the two groups. The relationship between the expression of RUNX3 and miR-363 with its clinicopathological characteristics was analyzed as well. The expression of RUNX3 in the experiment group was significantly lower than that in the control group (p<0.05). The expression level of miR-363 was significantly lower than in the control group (p<0.05). However, there was a correlation with tumor size, degree of differentiation, lymph node metastasis, depth of invasion and clinical stages (p<0.05). RUNX3 and miR-363 were significantly positively correlated with the degree of differentiation (r=0.7381, r=0.5375; p<0.05); RUNX3 and miR-363 were significantly negatively correlated with clinical stages (r=-0.7167, -0.6700; p<0.05). The area under the ROC curve of the combined test was larger than the single test. The expression of RUNX3 gene and miR-363 in peripheral blood of patients with colorectal cancer was lower than in the normal controls. The low expression of RUNX3 and miR-363 was closely related to various biological behaviors of colorectal cancer. A potential reference is provided for the evaluation of patients with colorectal cancer and expected to have an important guiding effect in the treatment of colorectal cancer. Moreover, combined test of RUNX3 and miR-363 has important significance in the diagnosis and treatment evaluation of colorectal cancer.

View Figures

View References

1	Wong MC, Lam AT, Li DK, Lau JT, Griffiths SM and Sung JJ: Factors associated with practice of colorectal cancer screening among primary care physicians in a Chinese population: A cross-sectional study. Cancer Epidemiol. 33:201–206. 2009. View Article : Google Scholar : PubMed/NCBI
2	Matsuoka K, Watanabe N and Nakamura K: O-glycosylation of a precursor to a sweet potato vacuolar protein, sporamin, expressed in tobacco cells. Plant J. 8:877–889. 1995. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zheng R, Zeng H, Zhang S, Chen T and Chen W: National estimates of cancer prevalence in China, 2011. Cancer Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
5	Wang XQ, Tang ZX, Yu D, Cui SJ, Jiang YH, Zhang Q, Wang J, Yang PY and Liu F: Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma. Oncotarget. 7:8823–8838. 2016.PubMed/NCBI
6	Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G and Kip KE: Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care. 34:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhong LL, Chen HY, Cho WC, Meng XM and Tong Y: The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis. Complement Ther Med. 20:240–252. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kim HJ, Park J, Lee SK, Kim KR, Park KK and Chung WY: Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer. J Pathol. 237:520–531. 2015. View Article : Google Scholar : PubMed/NCBI
9	Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, et al: RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 169:344–351. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 23:6736–6742. 2004. View Article : Google Scholar : PubMed/NCBI
11	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4. Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE and Corcione F: Worldwide burden of colorectal cancer: A review. Updates Surg. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cohen SJ, Cohen RB and Meropol NJ: Targeting signal transduction pathways in colorectal cancer - more than skin deep. J Clin Oncol. 23:5374–5385. 2005. View Article : Google Scholar : PubMed/NCBI
18	Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, et al FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group, : Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet. 370:143–152. 2007. View Article : Google Scholar : PubMed/NCBI
19	Croitoru ME, Cleary SP, Di Nicola N, Manno M, Selander T, Aronson M, Redston M, Cotterchio M, Knight J, Gryfe R, et al: Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 96:1631–1634. 2004. View Article : Google Scholar : PubMed/NCBI
20	Soong R, Shah N, Peh BK, Chong PY, Ng SS, Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer. 100:676–679. 2009. View Article : Google Scholar : PubMed/NCBI
21	Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M and Ito Y: Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 18:1225–1230. 2007.PubMed/NCBI
22	Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, et al: Similarity of aberrant DNA methylation in Barretts esophagus and esophageal adenocarcinoma. Mol Cancer. 7:752008. View Article : Google Scholar : PubMed/NCBI
23	Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A, et al: RUNX3 promoter methylation in colorectal cancer: Its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res. 30:2673–2682. 2010.PubMed/NCBI
24	Kang KA, Kim KC, Bae SC and Hyun JW: Oxidative stress induces proliferation of colorectal cancer cells by inhibiting RUNX3 and activating the Akt signaling pathway. Int J Oncol. 43:1511–1516. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X and Chen W: Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol. 45:513–520. 2013. View Article : Google Scholar : PubMed/NCBI
26	Luo X, Burwinkel B, Tao S and Brenner H: MicroRNA signatures: Novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev. 20:1272–1286. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xu X, Wu X, Wu S, Jiang Q, Liu H, Chen R and Sun Y: Study on miR-490-5p and miR-363 as novel biomarkers for the diagnosis of colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 17:45–50. 2014.(In Chinese). PubMed/NCBI
28	Watanabe T, Kobunai T, Ikeuchi H, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, et al: RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol. 38:201–207. 2011.PubMed/NCBI
29	Mu WP, Wang J, Niu Q, Shi N and Lian HF: Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: A meta-analysis. OncoTargets Ther. 7:1237–1245. 2014. View Article : Google Scholar
30	Tsuji S, Kawasaki Y, Furukawa S, Taniue K, Hayashi T, Okuno M, Hiyoshi M, Kitayama J and Akiyama T: The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nat Commun. 5:31502014. View Article : Google Scholar : PubMed/NCBI